Skip to main content
Premium Trial:

Request an Annual Quote

Big Blue and the Genome

IBM is getting in on the $1,000 genome race — and plan to bring that cost even lower, to $100. The company's approach is based on what it calls "DNA transistor," reports the New York Times. (Our sister publication GenomeWeb Daily News covers this here.) IBM plans to develop a silicon-based system containing a million nanopores through which DNA can be ratcheted to sequence a genome in a few hours. "To bring about an era of personalized medicine, it isn't enough to know the DNA of an average person," says IBM's Gustavo Stolovitzky. "As a community, it became clear we need to make efforts to sequence in a way that is fast and cheap." However, Elaine Mardis tells the Times that previous attempts to develop a silicon-based nanopore system didn't pan out. "DNA strands seem to have a mind of their own," she says.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.